02393 YESTAR HEALTH
- 0.051
- +0.001+2.00%
YESTAR HEALTH News
YESTAR HEALTH: Interim report 2024
YESTAR HEALTH: INTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2024
Hong Kong stocks soared with Star Creep Medical jumping by 123%, expecting a significant increase in mid-term net profit.
On August 19, Gelonghui: Giant Star Medical (2393.HK) surged 123.68% to HKD 0.085 in early trading, but the gain quickly narrowed to around 70%. However, it remains the stock with the largest increase in the Hong Kong stock market, but the trading volume is light, with only HKD 2.67 million turnover so far. The Group announced that its comprehensive net profit for the first half of the year is estimated to increase by no less than CNY 1.05 billion, or CNY 11.6 million, due to the redemption of the original 2026 maturity preference notes at a discount, which confirmed a considerable premium. At the same time, the redemption of relevant preference notes reduced financial costs.
The Hong Kong stock market is strong, with a stock soaring over 123% during intraday trading! What happened?
With the rise in market activity, the Hong Kong stock market has also seen frequent appearances of "monster stocks".
Mid-Day Overview | The three major indices are all up, with the tech index rising nearly 3%; JD.com leads the rise in network technology stocks with a more than 6% increase, while auto and golden industrial concept stocks are also strong.
Network technology stocks rose collectively, with jd.com up more than 6%, bilibili and netease up about 4%, baidu up more than 3%, xiaomi up 3%, alibaba and kuaishou up more than 2%, with meituan, tencent and others following the trend.
Yestar Health, a Hong Kong stock, once soared 100%.
On August 19th, Gelonghui reported that Yestar Health (2393.HK) once soared by 100%. The company expects a significant increase in comprehensive net profit in the first half of the year, not less than 1.05 billion yuan, and a net profit of about 11.6 million yuan in the first half of 2023.
Yestar Health (02393.HK) expected significant growth in net profit in the mid-term.
Yestar Health (02393.HK) announced that compared with the unaudited comprehensive net profit of approximately RMB 11.6 million for the first six months ended June 30, 2023, the unaudited comprehensive net profit for the mid-term period during 2024 is expected to increase significantly by no less than RMB 1,050 million. The expected significant increase in the group's mid-term net profit mainly comes from (i) confirming substantial premiums due to the redemption of the preferred notes originally due in 2026 at a discount price, and (ii) reducing financial costs after redeeming the related preferred notes.
C-Mer Eye Care Holdings Limited (02393.HK) expects its net profit for the first half of the year to increase by no less than 1.05 billion Hong Kong dollars compared to last year.
Jiuxing Medical (02393.HK) has announced a profit increase. It is expected that the comprehensive net profit for the first six months ending June this year will increase by no less than 1.05 billion yuan on a year-on-year basis. This is compared to a net profit of 11.6 million yuan in the same period last year. The group stated that the significant increase in net profit was mainly due to the confirmation of substantial gains from redeemed preferred notes originally scheduled to mature in 2026 at a discounted price; and the reduction of financial costs after redeeming the related preferred notes.
YESTAR HEALTH: POSITIVE PROFIT ALERT
Yestar Health (02393.HK) plans to hold a board of directors meeting on August 29 to approve the mid-term performance.
Yestar Health (02393.HK) announced on August 14 that the board of directors will hold a meeting on August 29, 2024 (Thursday), to (including) consider and approve the unaudited comprehensive mid-term performance of the company and its subsidiary companies for the six months ending June 30, 2024, as well as declare a mid-term dividend (if any).
Second Arbitration Related to Yestar Healthcare's Trading Firm Acquisition Terminated
Yestar Healthcare Narrows Loss in 2023
YESTAR HEALTH: ANNUAL REPORT 2023
Yestar Healthcare Faces Second Arbitration Related to Trading Firm Acquisition
Superstar Healthcare Holdings (02393): Leung Chun-hung resigns as executive director
Superstar Medical Holdings (02393) announced that Leung Chun-hung undertakes other duties related to his future career and business development...
Superstar Medical Holdings (02393) announced annual results. Losses attributable to shareholders of 13.888 million yuan narrowed 98.6% year-on-year
According to the Zhitong Finance App, Superstar Medical Holdings (02393) announced its annual results for the year ended December 31, 2023. The group achieved continuous business revenue of 2,913 billion yuan (RMB, same below) during the period, an increase of 3.86% over the previous year; losses attributable to shareholders were 13.888 million yuan, a year-on-year decrease of 98.6%; and a basic loss of 0.6 points per share. According to the announcement, demand for the Group's in vitro diagnostic consumables increased in 2023, mainly due to a sharp rise in demand for cardiomyocardial products from patients with diseases caused by COVID-19 in the first quarter of 2023. Receipts from continuing operations in this segment
YESTAR HEALTH: ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Superstar Medical Holdings (02393.HK) expects net loss of not more than 10 million yuan in fiscal year 2023
Gelonghui, March 15, 丨 Superstar Medical Holdings (02393.HK) announced that compared to the Group's audited net loss of approximately RMB 1.02 billion for the year ended December 31, 2022, the Group expects a sharp reduction in fiscal year 2023 and recorded a net loss of not more than RMB 10 million. The Group expects a sharp decrease in net losses in fiscal year 2023 mainly due to (i) a sharp reduction in impairment losses on goodwill and other intangible assets in fiscal year 2023; (ii) impairment losses on the return of some financial assets; and (iii) a sharp drop in financial costs.
YESTAR HEALTH: PROFIT WARNING
Superstar Healthcare Holdings (02393.HK) held a board meeting on March 27 to consider and approve the annual results
Glonghui, March 15, 丨 Superstar Healthcare Holdings (02393.HK) announced that the company will hold a board meeting on March 27, 2024 (Wednesday) to consider and approve (among other things) the annual results of the company and its subsidiaries for the year ended December 31, 2023, and to recommend payment of a final dividend (if any).
Analysis
Price Target
No Data
No Data